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Abstract: Influenza B virus (IBV) circulates in the human population and causes considerable 
disease burden worldwide, each year. Current IBV vaccines can struggle to mount an effective cross-
reactive immune response, as strains become mismatched, due to constant antigenic changes. 
Additional strategies which use monoclonal antibodies, with broad reactivity, are of considerable 
interest, both, as diagnostics and as immunotherapeutics. Alternatives to conventional monoclonal 
antibodies, such as single domain antibodies (NanobodiesTM) with well-documented advantages for 
applications in infectious disease, have been emerging. In this study we have isolated single domain 
antibodies (sdAbs), specific to IBV, using alpacas immunised with recombinant hemagglutinin (HA) 
from two representative viruses, B/Florida/04/2006 (B/Yamagata lineage) and B/Brisbane/60/2008 
(B/Victoria lineage). Using phage display, we have isolated a panel of single domain antibodies 
(sdAbs), with both cross-reactive and lineage-specific binding. Several sdAbs recognise whole virus 
antigens, corresponding to influenza B strains included in vaccines spanning over 20 years, and 
were capable of neutralising IBV pseudotypes corresponding to prototype strains from both 
lineages. Lineage-specific sdAbs recognised the head domain, whereas, sdAbs identified as cross-
reactive could be classified as either head binding or stem binding. Using yeast display, we were 
able to correlate lineage specificity with naturally occurring sequence divergence, at residue 122 in 
the highly variable 120 loop of the HA1 domain. The single domain antibodies described, might 
have applications in IBV diagnostics, vaccine potency testing and as immunotherapeutics. 
Keywords: influenza; influenza B virus; hemagglutinin; single domain antibody; NanobodyTM; 
phage display; yeast display; epitope mapping 
 
1. Introduction 
Seasonal influenza caused by the influenza A virus (IAV) and the influenza B virus (IBV) 
remains a considerable public health challenge [1]. IBV has received less attention than IAV, largely 
because it does not cause pandemics as there are no naturally occurring, non-human reservoirs to 
facilitate the extensive antigenic changes, characteristic of a pandemic. However, there has been a 
recent increase in the rate of IBV infection, globally, with between 2030% of the total influenza 
burden now due to influenza B [2]. Current vaccines can struggle to induce sufficient levels of cross-
protective immunity against IBV and strains often become mismatched, due to the constant antigenic 
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changes in the influenza virus [3]. The virus also co-circulates as two antigenically distinct lineages 
and, therefore, the dominant circulating lineage must be predicted for inclusion in the trivalent 
vaccine. This highlights the need to develop additional approaches to both treat and protect from the 
influenza B virus infection. Passive immunotherapy, using broadly neutralising antibodies against 
the major viral coat protein hemagglutinin (HA), is one approach that has shown great promise for 
the treatment of IAV infection [4]. The precursor HA protein (HA0) is cleaved by the host proteases 
into a form that comprises a highly variable distal head domain, HA1, and a more conserved 
proximal stem region, HA2 [5]. Most broadly, neutralising anti-HA monoclonal antibodies that have 
been described to date, target the HA stem of IAV [6,7,8]; however, monoclonal antibodies with broad 
reactivity have been described, which bind the more variable head domain, using a single CDR3 loop 
for antigenic recognition [9]. The more recently reported broadly neutralising monoclonal antibodies 
against IBV have also shown the presence of conserved epitopes, in both the stem region and the 
head domain [10,11,12]. A feature common between the broadly neutralising human monoclonal 
antibodies against both IBV and IAV, is the low levels of somatic hypermutation and heavy-chain-
only binding [7,10]. Heavy-chain-only binding has been suggested to be the preferred mode of 
binding to influenza HA, as has been described for HIV [13]. These observations highlight that the 
VL domain might not be required for binding occluded epitopes onto the HA stem. Guided by these 
observations, we have isolated naturally occurring heavy-chain-only antibodies from camelids (also 
known as NanobodiesTM), believing their small size, single domain structure and long CDR3 loops 
make this unique antibody format well-equipped to access similar HA stem epitopes [14,15,16]. 
In the 1980s, the influenza B virus diverged to give two distinct lineages, termed the 
B/Yamagata/16/88 and B/Victoria/2/87 lineages [17]. Although the HA stem region remains highly 
conserved, the head domain has diverged to become sufficiently antigenically and genetically 
distinct, to warrant an independent inclusion in the current quadrivalent influenza vaccines [18]. The 
inclusion of seasonal strains from both IBV lineages, in turn, presents a challenge for both vaccine 
production and potency determination. Separate monoclonal antibodies, with either B-Victoria or B-
Yamagata lineage-specific recognition could find applications in determining the individual 
antigenic content of each IBV lineage strain included in the seasonal vaccines [19]. However, the 
challenge in identifying lineage-specific binding antibodies is that, such epitopes are expected to be 
in the more variable head domain of the HA and, as such, are susceptible to antigenic change with 
associated loss of reagent binding. The degree of antigenic divergence, tolerated by a given 
monoclonal antibody binding to the variable head domain, which is subject to constant selective 
pressure to change, to some extent, is determined by the size of the epitope footprint. It is interesting 
to speculate that a small epitope footprint could be an advantage, as there may be less amino acid 
mutations that can impact antibody reagent binding. Single domain antibodies isolated from 
camelids, have preferences for smaller crevices and clefts on protein surfaces, as compared to the 
conventional two-chain monoclonal antibodies, which generally bind to larger flatter epitopes 
[20,21]. As such, single domain antibodies (sdAbs) may have a smaller epitope footprint and, 
therefore, might be able to retain binding to a constantly changing virus, for longer. In addition, 
human monoclonal antibodies to the HA head domain derived from either naturally infected or 
vaccinated patients might have already contributed to the antigenic pathways of viral escape and 
might be pre-ordained to the loss of binding. For these reasons, we have chosen to isolate the IBV 
lineage-specific sdAbs, rather than the conventional MAbs (Monoclonal Antibodies), believing that 
this unique antibody format could also form the basis of a robust and durable immunoassays for 
potency determination of the IBV containing vaccines [19]. 
By immunising alpacas with recombinant HA and the selection of phage display libraries, we 
have isolated sdAbs with both cross-reactivity and lineage-specific recognition. Through combining 
conventional phage display selections and next-generation sequencing, we have isolated rare sdAbs 
with either B-Victoria or B-Yamagata lineage specificity. We have grouped sdAbs, on the basis of 
head or stem binding, and used yeast display, to further de-lineate an epitope associated with B-
Victoria lineage-specific recognition. The potential applications of these different classes of sdAbs for 
applications in the IBV vaccine potency assays and as immunotherapeutics, are also discussed. 
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2. Materials and Methods  
2.1. Influenza Antigens and Immunisation of the Alpacas 
The virus antigen standards used in this study were B/Brisbane/60/2008 (National Institute for 
Biological Standards and Control (NIBSC) 14/146), B/Malaysia/2506/2004 (NIBSC 08/184), 
B/Shangdong/9/97 (NIBSC 04/128), B/Victoria/2/87 (NIBSC 87/774) of the B-Victoria lineage; the 
B/Yamagata/16/88 (NIBSC 92/628), B/Yamanashi/166/98 (NIBSC 99/586), B/Harbin/7/94 (NIBSC 
97/748), B/Jiangsu/10/2003 (NIBSC 04/202), B/Florida/4/2006 (NIBSC 08/140), 
B/Massachusetts/02/2012 (NIBSC 13/106), B/Phuket/3037/2013 (NIBSC 14/252), B/Utah/9/2014 (NIBSC 
15/100) of the B-Yamagata lineage; and the pre-lineage split strain B/HongKong/8/73 (NIBSC 79/568). 
Seasonal H1N1 strain A/Brisbane/10/2007 (NIBSC 08/278) was used as a negative control. Purified 
recombinant hemagglutinins used in this study were B/Brisbane/60/2008 (B-Victoria) and 
B/Florida/04/2006 (B-Yamagata) (Protein SciencesTM, Meriden, CT, USA). Purified HA1 head domains 
from B/Brisbane/60/2008 (B-Victoria) and B/Florida/04/2006 (B-Yamagata) were also used (Sino 
BiologicalsTM, Beijing, China). Juvenile male alpacas were purchased through the Royal Veterinary 
College, Hertfordshire, UK. All experiments were reviewed by a local ethics committee and 
performed under a U.K Home Office licence PPL 80/2581. A blood sample, prior to immunization, 
was obtained from the external jugular vein and this was followed by four intramuscular injections 
on day 0 (primary immunisation), 21, 43 and 71, with injections being administered to the rear legs 
(thigh region) on days 0 and 43, and to the front legs (thigh region) on days 21 and 71. The primary 
immunisation consisted of 50 µg of recombinant HA B/Brisbane/60/2008 (B-Victoria) or 
B/Florida/04/2006 (B-Yamagata) (ProteinSciencesTM) in 400 µL of sterile PBS (phosphate buffered 
saline) , which was emulsified with 800 µL of Freunds complete adjuvant (Sigma Aldrich St. Louis, 
MO, USA), just prior to immunisation. Similarly, the three booster injections of 50 µg of the same 
recombinant HA as the primary immunisation in Freunds incomplete adjuvant (Sigma), were 
administered. Approximately four days after each injection, a 10 mL blood sample was collected from 
the external jugular vein, from which the serum was prepared, after allowing the blood to clot 
overnight at 4 °C. 
2.2. Construction and Selection of the Phage-Displayed Libraries 
For the antibody library construction, approximately 10 mL blood samples were collected into 
the heparinised tubes, from an immunised alpaca. Peripheral blood mononuclear cells were purified 
using a Ficol Hypaque centrifugation procedure (Sigma) and RNA was extracted using a RiboPureTM 
RNA extraction kit (Novagen, Thermo Fisher Scientific, Waltham, MA, USA) following the 
manufacturers instructions. First strand cDNA synthesis was performed using Superscript IIITM 
reverse transcriptase (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) and oligo-dT 
primer with 200 ng of total RNA per reaction. Primary PCR and secondary PCR to recover the alpaca 
VHH genes (DNA encoding the variable region of the heavy-chain-only antibodies) appended with 
Sfi1 and Not1 restriction sites were carried out, as previously described [14]. Approximately 5 µg of 
the VHH antibody DNA was digested by the Not1 and SfiI restriction enzymes (New England 
BioLabs, Ipswich, MA, USA) and then ligated into a phage-display vector, pNIBS-1, which contains 
a His tag for sdAb purification, a Myc tag for detection and a suppressible stop codon for soluble 
expression [14]. After purification (Qiagen, Hilden, Germany), the ligation mix was transformed into 
the TG1 electro-competent cells (Agilent, Santa Clara, CA, USA), using electroporation. Phage 
antibody library selections were performed using immunotubes (Nunc, Thermo Fisher Scientific, 
Waltham, MA, USA) coated overnight, at 4 °C, with 1 mL of the 10 µg/mL recombinant HA (Protein 
SciencesTM) in PBS or the whole virus antigen standards reconstituted in PBS [14]. 
2.3. Antibody Expression and Screening 
Individual colonies from each round of selection were picked and grown overnight, at 37 °C, in 
2 × TY supplemented with carbenicillin (100 µg/mL) and 2.0% (w/v) glucose and plasmid DNA was 
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isolated (Qiagen, Hilden, Germany). Cloned VHH genes were sequenced, aligned and grouped, 
according to the CDR3 length and homology. CDR3 sequences of high homology and identical length 
were assumed to have been derived from clonally related B cells and were likely to bind to the same, 
or overlapping, epitope on HA. Representative members from each proposed epitope group were 
expressed and purified. For single domain antibody production, pNIBS-1 clones were transformed 
into the non-suppressor Escherichia coli strain WK6 (New England Biolabs). Soluble antibody 
expression was induced with the addition of IPTG to the 1 mM final concentration, followed by a 
further incubation, overnight, at 30 °C. Periplasmic extracts were prepared [14] and purified by 
immobilised metal chelate chromatography (IMAC), using Ni-NTA spin columns (Qiagen) or 
TALONTM resin (Clontech, Takara Bio Inc. Mountain View, CA, USA), according to manufacturers 
instructions, depending on the scale. Purified samples were then dialysed, using Slide-A-Lyzer 
cassettes with a 3.5 kDa molecular weight cut-off (Pierce, Thermo Fisher Scientific, Waltham, MA, 
USA) into the PBS and the size and purity assessed by the SDS-PAGE. Purified single domain 
antibodies were screened for binding to the recombinant HAs and to the influenza virus antigen 
standards. Influenza virus antigen standards (National Institute for Biological Standards and Control, 
NIBSC) were reconstituted in 1 mL sterile water and then diluted 1/20 in PBS (prior to incubation) 
overnight, at 4 °C, in a 96-well plate (Nunc), followed by ELISA using an HRP (horseradish 
peroxidase) conjugated anti-c-Myc secondary reagent and TMB (3,3,5,5 tetramethylbenzidine) 
detection at OD450nm [14]. 
2.4. Analysis Using Surface Plasmon Resonance 
For binding and affinity ranking, a BIAcore T100 machine (GE Healthcare, Marlborough, MA, 
USA) was used, in combination with a single-cycle kinetics procedure [22]. In brief, the purified 
recombinant hemagglutinins from different Influenza B viruses were immobilised onto a BIAcoreTM 
CM5 chip in 10 mM sodium acetate pH 5.5, using an amine coupling kit (GE Healthcare), to 
approximately 3,000 RU. A concentration series from 1 nM100 nM of purified sdAbs were run over 
the different antigen surfaces. A reference surface was subtracted, prior to evaluation of the 
sensorgrams, using the single-cycle kinetics procedure of the BIAevaluationTM software (GE 
Healthcare) and a 1:1 fitting model. Binding the full length HA0 or the head domain, HA1, of 
hemagglutinin was evaluated using the recombinant B-Victoria HA0, B/Brisbane/60/2008, and B-
Yamagata HA0, B/Florida/04/2006, (Protein SciencesTM) or B-Victoria HA1, B/Brisbane/60/2008, and 
B-Yamagata HA1, B/Florida/04/2006, (Sino Biological Inc, Beijing, China). 
2.5. Next-Generation-Sequence-Assisted Single Domain Antibody Discovery 
Plasmid DNA was extracted from E. coli cultures grown from pre- and post-selection libraries 
(Figure 1), to obtain template DNA for the next-generation sequencing (NGS). A primary PCR 
reaction was performed using Phusion Hot Start II High Fidelity Polymerase (ThermoFisher 
Scientific) and the primers: NGS_Alp_Fr1_Q (5ȝ-
tcgtcggcagcgtcagatgtgtataagagacagCAGCCGGCCATGGCACAG-3ȝ) and NGS_FR4_Rev_AD (5ȝ-
gtctcgtgggctcggagatgtgtataagagacagTGAGGAGACGGTGACCTG-3ȝ), which encoded the VHH gene 
flanking plasmid sequence (upper case) and adaptor sequences for the Nextera XT indexing (lower 
case), resulting in PCR products between 450bp and 550bp. The PCR products were purified (Qiagen) 
and used as a template for a secondary low-cycle number indexing PCR, using a Nextera XT indexing 
kit (Illumina, San Diego, CA, USA). Resulting PCR products were purified (Qiagen), quantified using 
the Qubit 2.0 fluorimeter (ThermoFisher Scientific) and the DNA1000 Kit (Agilent Technologies, 
Santa Clara, CA, USA), followed by quality checking, using the Bioanalyzer 2100 (Agilent 
Technologies). Samples were prepared and multiplexed for use with the MiSeq reagent kit v3 (2 × 300 
cycle) and run on the Illumina MiSeq, according to the manufacturers protocol. The de-multiplexing 
and trimming of sequences were performed on the Illumina MiSeq instrument. Copy numbers of the 
individual CDR3ȝs were obtained from the reverse read FastQ files, using the antibody mining 
toolbox [23]. Our intention at this stage was not a full-length sdAb repertoire analysis but to identify 
the unique high frequency CDR3ȝs, which were highly enriched by the selection of Influenza B HA1 
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domain, compared to their frequency in the original phage library. Relative frequency of each CDR3, 
as a percentage of the total, was determined by dividing the individual CDR3 copy number by a total 
CDR3 copy number ×100 (%RF) and the enrichment level (fold) was determined by the CDR3 %RF, 
after selection, divided by the CDR3 %RF, in the absence of any selection (the original phage library). 
Candidate CDR3ȝs from the selections on recombinant HA1 that showed high levels of enrichment, 
were compared with the enrichment levels of the same CDR3ȝs in the selections of full-length HA0. 
Full-length DNA sequence for four sdAbs containing these highly enriched candidate CDR3ȝs were 
then obtained, using the DNA sequence of the CDR3 of interest, to search the reverse read FastQ file 
using the Geneious 7.1.2 (https//www.geneious.com), combining the sequences found with the 
corresponding forward reads from the forward FastQ file. Sequences were synthesised (IDT), the 
sdAbs were expressed and purified, as before, and the binding specificities were determined by 
ELISA. 
 
Figure 1. Selection strategies to isolate cross-reactive and lineage-specific single domain antibodies 
(sdAbs) against influenza B hemagglutinin. The figure shows the immunisation approaches, 
selection and screening strategies. The number of VHH CDR3 sequences isolated from each 
approach is indicated. 
2.6. Lentiviral Pseudotype Assays 
Lentiviral pseudotypes were produced by transient co-transfection of HEK293T/17 cells, using 
polyethylenimine [24,25]. Plasmid p8.91 encodes the structural (gag, pol) genes, whereas, pCSFLW 
represents the genome incorporated into the pseudotypes, bearing the firefly luciferase reporter. 
Influenza B hemagglutinin genes, in the expression plasmid pI.18, were also added to this mix, 
alongside the Human Airway Trypsin (HAT) expression plasmid, pCAGGS-HAT to allow for HA0 
to HA1/2 maturation. The pseudotype-based microneutralisation assay (pMN) was carried out in 
NuncTM F96 microplates (Thermo Fisher Scientific) [24,25]; 1:2 serial dilutions were performed with 
the relevant sdAbs, across the 96-well plate in a total of 50µL DMEM (10% foetal bovine serum, 1% 
penicillin/streptomycin). HIV-1-derived lentiviral pseudotypes, bearing the influenza B HA of choice, 
was then added to yield a relative luminescence unit (RLU) input of 1.5 × 106 per well, in a total 
volume of 50 µL [26]. The plates were then incubated in a humidified incubator at 37 °C, 5% CO2, for 
one hour, after which 1 × 104 HEK293T/17 cells were added, per well, in a total volume of 50µl. After 
48h, the supernatants were removed and a 50:50 mix of PBS and Bright-GloTM (Promega, Madison, 
WI, USA) was added to each well. Plates were incubated at room temperature, for five minutes, and 
then luminescence was read using a Glomax® luminometer (Promega). Results were normalised to 
cell and virus only controls, representing 100% and 0% neutralization, respectively, and IC50 values 
were calculated by non-linear regression, using GraphPad 5 Prism. 
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2.7. Construction and Screening of a Randomly Mutagenised HA Library Using Yeast Display 
The coding sequence of the Influenza B virus hemagglutinin (HA0) of the strain 
B/Brisbane/60/2008 (GenBank FJ766840.1, minus the N-terminal signal sequence and the C-terminal 
transmembrane domain, comprising amino acids D1-I534) was codon-optimised for expression in 
yeast and synthesised, with 5ȝ SfiI and 3ȝ NotI restriction sites (IDT). The construct was cloned as a 
SfiI/NotI restriction fragment into the yeast display vector pNIBS-5 [16], which carried an SV5 tag, 
and transformed into Saccharomyces. cerevisiae EBY100 (Invitrogen), using a yeast transformation kit 
(Sigma).  
A library of the HA0 mutants was generated by error-prone PCR, at a low error rate, to give 
approximately, 1 mutation per HA gene [16]. Approximately 20 µg of the HA0 error-prone PCR 
product was co-transformed with 20 µg of the Sfi1/Not1 digested pNIBS-5 vector, into the EBY100 
competent cells, for a recombination between the PCR products and the yeast vector to take place in 
the yeast cells [16]. Standard procedures and recipes for growth, induction, yeast cell labelling, media 
and buffer preparation were used [16]. Staining for the sdAb binding to HA0 was performed by 
incubating yeast cells with 200 nM of purified sdAbs (c-Myc tagged), followed by a chicken anti c-
Myc antibody (Bethyl Laboratories, Montgomery, TX, USA), and then by a goat-anti-chicken IgG 
AlexaFluor647-labelled secondary antibody (Jackson ImmunoResearch Europe, Ely, UK). Staining of 
yeast cells for HA0 display was performed by incubating yeast cells with mouse monoclonal anti-
SV5 antibody (AbSerotec, Bio-Rad, Hercules, CA, USA), followed by a goat anti-mouse IgG 
AlexaFluor488-labelled secondary antibody (ThermoFisher scientific). Staining was performed 
simultaneously for the sdAb binding and the HA0 display. The mutant yeast library was grown in a 
selective medium for induction of the HA display and, approximately, 106 cells were co-stained with 
purified sdAbs at 200 nM, followed by anti-SV5 and anti-c-Myc detection antibodies, and then by 
fluorescent secondary antibodies, as above [16]. Flow cytometric cell sorting was performed using 
the BDAria III and FACSDiva software v8.0.1 (Becton Dickenson, Franklin Lakes, NJ, USA). A sorting 
gate was chosen to sort cells for the display of HA0 (by virtue of the anti-SV5 signal), but also for the 
absence of sdAb binding. A second round was then performed using the same conditions. Yeast DNA 
minipreps were made from the final round of sorting and transformed into the TG1 electro-
competent Escherichia coli cells (Agilent). Then, plasmids from single bacterial colonies were 
sequenced. Resulting sequences were aligned to wt HA0 (wild-type B/Brisbane/60/2008 HA0), using 
Geneious 7.1.2 (https//www.geneious.com) to identify candidate mutations. Plasmids containing 
single residue candidate mutations were re-created, where required, using the QuikChangeII site 
directed mutagenesis kit (Agilent) and re-transformed into yeast cells. Individual yeast clones 
containing either a mutant HA0 or a yeast containing the wt HA0, were grown in a selective medium, 
for induction of the HA display and cells stained for display and sdAb binding, as above. Binding of 
each sdAb to each mutant HA0 and wt HA0 yeast clone was determined by flow cytometry on a 
FACS CantoII flow cytometer (Becton Dickinson). Data collection and analysis was performed using 
the FACSDiva and FlowJo v10, (LLC, Ashland, OR, USA) software. 
3. Results 
3.1. Isolation and Characterisation of Cross-Reactive and Lineage-Specific Single Domain Antibodies against 
the Influenza B Hemagglutinin 
Two phage displayed sdAb libraries were constructed from purified peripheral blood 
mononuclear cells of alpacas immunised with recombinant HA0 from the representative B-Victoria 
(B/Brisbane/60/2008) or B-Yamagata (B/Florida/04/2006) lineage viruses. The size of the B-Victoria 
library was 9.4 × 107 independent clones and the B-Yamagata library was 3.7 × 107 independent clones. 
Each phage library was selected for two rounds on the HA antigen used for immunization, for an 
unbiased recovery of all sdAbs binding to the immunogen. To bias for the selection of cross-reactive 
sdAbs, a second strategy was also performed, by alternating selections between the B-Victoria lineage 
and the B-Yamagata lineage antigens (Figure 1).  
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After selection, sdAbs were sequenced and grouped into clonally related families, based on the 
CDR3 sequence length and similarity. Single domain antibodies with identical CDR3 length and high 
sequence similarity were assumed to be clonally related and, thus, binding to the same or overlapping 
epitopes, so a single representative clone from each family was taken forward for further analysis. 
Our ELISA screening identified sdAbs with a pre-dominantly cross-lineage reactivity (Figure 2), 




























































































Figure 2. ELISA showing sdAb binding to the recombinant hemagglutinin (HA0). sdAb binding to 
the recombinant HA0 from Influenza B-virus lineage representative strains used in immunisations 
and phage display library selections. B-Vic is B/Brisbane/60/2008, B-Yam is B/Florida/04/2006. Control 
sdAb A2c-3 is specific for influenza A hemagglutinin, PBS is a no sdAb negative control. ELISA signal 
is an average of 2 assays. 
In addition to cross-lineage reactive sdAbs, we were able to identify Vic2a-6 with B-Victoria 
lineage-specific recognition, however, we were unable to isolate any B-Yamagata lineage-specific 
sdAbs, using the conventional screening. We reasoned that epitopes defining B-Yamagata lineage 
specificity would be rare and likely to bind to the more variable HA1 head domain [5]. Therefore, we 
selected the B-Yamagata phage display library on a purified recombinant HA1 domain of 
B/Florida/4/2006, to bias against the stem reactive sdAbs, which had dominated previous selection 
strategies, and then used next-generation sequencing to identify new unique CDR3 sequences [27]. 
Highly enriched CDR3 sequences were identified, relative to the unselected CDR3 pool, and 
compared to those sequences already recovered, using conventional phage display selections. This 
led to the identification of several VHH CDR3 sequences which had not previously been identified 
(Figure S1). Full-length VHH sequences were synthesised and four candidate sdAbs were expressed 
and tested for B-Yamagata lineage-specific recognition, resulting in one unique B-Yamagata lineage-
specific sdAb, YamNGS#1. A final panel of thirteen unique sdAbs were taken forward, which 
included eleven cross-lineage reactive sdAbs, one B-Victoria lineage, and one B-Yamagata lineage-
specific sdAb (Table 1) (Figure 1). All sdAbs were shown to have the characteristic camelid heavy-
chain-only antibody framework 2 hallmark residue substitutions [28]. CDR3 lengths varied from 5 
to 20 residues (Table 1) and all sdAbs were expressed at yields between 3 mg/litre to 27 mg/litre. 
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Table 1. VHH CDR3 sequences of specific single domain antibodies.  
Nanobody CDR3 sequence B-Yamagata B-Victoria 
Vic2b-3 AADAVVAGPDDEYDY + + 
Yam2a-10 NVGFNY + + 
Vic2a-20 ASKGTDYIDGIYYISYQFNS + + 
Vic2a-6 VASPFSTGRATLPYQYPY - + 
YamNGS#1 AAASLCSFSSNDYFY + - 
Yam2b-9 AAGSGGRYDY + + 
Vic1b-10 NAPTYSN + + 
Yam1b-9 ALGDFTGLTNLRQAFYDF + + 
Yam2a-1 NFPRSSS + + 
Yam2c-16 NTHDY + + 
Vic2c-8 ALGDFSGSLWAYEYDF + + 
Yam1b-6 AAAKGGGAYSMISAYTY + + 
Yam2b-2 RLDHWLVSGY + + 
Binding to recombinant HA0 from the B-Victoria strain (B/Brisbane/60/2008) and the B-Yamagata 
strain (B/Florida/04/2006) in ELISA, indicated as binding (+) or not binding (-). 
We tested the extent of cross-reactivity on a panel of whole virus antigen standards, 
corresponding to the strains included in seasonal vaccines between 1973 and 2014 (Table 2). Most of 
the sdAbs initially identified as cross-reactive with the B lineage representative strains 
B/Brisbane/60/2008 (B-Victoria) and B/Florida/04/2006 (B-Yamagata), used for library construction 
(Table 1), showed extensive cross-reactivity going, both, forward and backwards in time, including 
the pre-lineage split strain (B/HongKong/08/73).
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Table 2. Single domain antibody recognition of the whole virus antigen standards by ELISA. 
Antigen Standard Year Vic2b-3 Yam2a-10 Vic2a20 Vic2a-6 YamNGS#1 Yam2b-9 Vic1b-10 Yam1b-9 Yam2a-1 Yam2c-16 Vic2c-8 Yam1b-6 Yam2b-2 
B/Brisbane/60/2008 2008 0.34 0.16 2.30 2.42 0.08 0.45 0.79 0.30 0.82 0.45 0.29 0.50 0.07 
B/Malaysia/2506/2004 2004 0.07 0.08 3.54 1.93 0.09 0.68 1.39 0.40 1.43 0.72 0.40 0.59 0.07 
B/Shangdong/7/97 1997 0.39 0.14 2.58 0.32 0.06 0.69 0.96 0.30 0.92 0.51 0.28 0.31 0.08 
B/Victoria/2/87 1987 0.43 0.20 3.31 0.86 0.09 0.56 1.27 0.83 1.35 1.15 0.77 1.04 0.11 
B/HongKong/8/73 1973 0.46 0.39 0.06 0.07 0.13 0.34 1.48 0.66 1.41 0.72 0.56 0.29 0.09 
B/Yamagata/16/88 1988 0.83 1.76 2.41 1.07 0.09 1.59 1.85 0.98 1.79 1.01 0.87 0.71 0.12 
B/Yamanashi/166/98 1994 0.74 1.08 0.11 0.07 0.07 1.70 2.16 1.34 2.41 1.35 1.24 1.70 0.14 
B/Harbin/7/94 1994 0.28 0.26 0.14 0.09 0.44 0.38 0.57 0.27 0.52 0.36 0.27 0.30 0.06 
B/Jiangsu/10/2003 2003 0.46 0.71 1.16 0.08 0.59 0.66 1.32 0.53 1.33 0.46 0.53 0.23 0.06 
B/Florida/4/2006 2006 0.42 0.40 0.16 0.07 0.83 0.62 0.64 0.20 0.68 0.31 0.18 0.32 0.07 
B/Mass'/02/2012 2012 0.53 0.82 0.79 0.05 1.00 3.03 1.82 0.94 1.96 0.85 0.84 1.57 0.10 
B/Phuket/3073/2013 2013 0.58 1.22 0.15 0.06 0.11 1.01 0.94 0.55 0.96 0.45 0.52 0.32 0.08 
B/Utah/9/2014 2014 0.90 1.36 0.14 0.07 0.10 0.31 1.13 0.52 1.20 0.43 0.50 0.21 0.05 
A/Brisbane/10/2007 2007 0.05 0.06 0.07 0.07 0.07 0.06 0.06 0.07 0.06 0.07 0.06 0.07 0.07 
B-Victoria strains ranging from 19872008 and B-Yamagata strains from 19882014. Pre-lineage split strain highlighted in red. Influenza B strains used as immunogens for 
the sdAb library generation are highlighted in blue. Influenza A strain control highlighted in green. Table arranged to show strains moving away from pre-lineage split in 
time, with most recent strains being the farthest away. Values shown are the average of two independent assays. sdAb binding was tested at a single concentration of 10 
µg/mL. OD450 > 1.0, OD450 >0.5, OD450 > 2 × negative control for each sdAb. B/Mass/02/2012 is B/Massachusetts/02/2012. 
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Single domain antibodies Yam2b-9, Vic1b-10, Yam 1b-9, Yam2a-1, Yam2c-16, Vic2c-8, and 
Yam1b-6 recognised all antigen standards tested from the pre-lineage split virus B/HongKong/8/73, 
up to more recent vaccine viruses B/Brisbane/60/2008 (B-Victoria lineage) and B/Utah/9/2014 (B-
Yamagata lineage). The B-Victoria lineage-specific sdAb Vic2a-6 showed reactivity to all B-Victoria 
strains tested between 19872008, but also bound the earliest B-Yamagata strain 
(B/Yamagata/16/1988), just post-split. YamNGS#1 was identified as having B-Yamagata lineage-
specific binding and was able to recognize the Yamagata strains between 1994 and 2012, covering a 
duration of eighteen years (Table 2). 
3.2. Grouping sdAbs on the Basis of HA1 Head Domain or Stem Domain-Specific Binding 
Single domain antibodies were tested for binding to the head domain, or the HA stem region, 
using surface plasmon resonance on both full-length recombinant HA0 and HA1 (head domain) from 
representative B-Yamagata and B-Victoria strains (Table 3, Supplementary Figure S2). 





B Yam HA11 
B/Florida 
/4/2006 
B Yam HA02 
B/Florida 
/4/2006 
B Vic HA11 
B/Brisbane 
/60/2008 




Vic2b-3 0.27nM 1.57nM 0.06nM 0.11nM Head Cross reactive 
Yam2a-10 3.49nM 6.70nM +3 3.30nM Head Cross reactive 
Vic2a-20 173nM - 0.79nM 0.48nM Head Cross reactive 
Vic2a-6 - - 0.07nM 0.08nM Head B-Vic lineage 
YamNGS#1 11.8nM 2.39nM - - Head B-Yam lineage 
Yam2b-9 - 2.13nM - 10.0nM Stem Cross reactive 
Vic1b-10 - 0.28nM - 1.1nM Stem Cross reactive 
Yam1b-9 - 0.10nM - 0.08nM Stem Cross reactive 
Yam2a-1 - 0.14nM - 7.40nM Stem Cross reactive 
Yam2c-16 - 1.46nM - 0.76nM Stem Cross reactive 
Vic2c-8 - 0.13nM - 0.37nM Stem Cross reactive 
Yam1b-6 - 5.43nM - 0.60nM Stem Cross reactive 
Yam2b-2 - 10.0nM - 1.36nM Stem Cross reactive 
1 HA1 is purified hemagglutinin head domain (Residues Met1-Arg361 of B/Florida/04/2006 and 
residues Met1-Arg362 of B/Brisbane/60/2008). 2 HA0 is purified full-length hemagglutinin. 3 Binding 
could be seen but could not be resolved using the BIAevaluationTM software. 
Five sdAbs were shown to be specific to the HA1 domain and eight sdAbs only showed 
recognition of the full-length HA0. Most of the cross-reactive sdAbs were classified as stem-specific, 
however, three sdAbs were predicted to bind cross-reactive epitopes in the head domain. The B-
Victoria lineage-specific sdAb Vic2a-6, bound to the head domain of the B/Brisbane/60/2008 (B 
Victoria), but did not bind to the B/Florida/04/2006 head domain or the full-length HA (B-Yamagata), 
which was consistent with recognition of a B-Victoria lineage-specific epitope in the head domain. 
YamNGS#1 bound to the head domain of the B/Florida/04/2006 (B-Yamagata), but showed no binding 
to the head domain of the B/Brisbane 60/2008 (B-Victoria), indicating that it binds to a B-Yamagata 
lineage-specific epitope in the head domain. The sdAbs had a high affinity down to <100 pM, 
reflecting the affinity maturation possible using the prime and boost immunisation of alpacas. The 
panel of sdAbs were grouped as cross-reactive head binding (Vic2b-3, Yam2a-10, Vic2a-20), cross-
reactive stem binding (Yam 2b-9, Vic1b-10, Yam1b-9, Yam2a-1, Yam2c-16, Vic2c-8, Yam1b-6, Yam2b-
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2), B Victoria lineage-specific head binding (Vic2a-6) or B-Yamagata lineage-specific head binding 
(YamNGS#1) (Table 3). 
3.3. In vitro Neutralisation Activity of Single Domain Antibodies 
Purified sdAbs were tested for their ability to neutralise influenza virus pseudotypes, 
corresponding to the different IBV lineages, using micro-neutralisation assays [24]. Six of the eight 
sdAbs identified as cross-reactive and binding to the epitopes in the HA stem region, were shown to 
be capable of neutralising pseudoviruses of both lineages with the most potent sdAb, Vic1b-10, 
having IC50 values of 0.2 nM and 15.5 nM on B-Vic and B-Yam lineage viruses, respectively (Table 
4). Yam2b-9 and Yam2b-2, although cross-reactive on the recombinant antigen (Figure 2, Table 3), 
showed only a lineage-specific neutralisation activity. There was generally a good correlation 
between affinity and neutralisation activity, except for Vic2c-8, which was shown to be the least 
potent in neutralization, despite having an affinity comparable to the other cross-reactive, sdAbs 
(Table 3, Table 4). 




















Vic2b-3 104 81 246 240 
Yam2a-10 - - - - 
Vic2a-20 - 1.1 - 112 
Vic2a-6 315 159 - 10 
YamNGS1#1 - - NT NT 
Yam2b-9 30.5 - NT NT 
Vic1b-10 0.2 15.5 NT NT 
Yam1b-9 31.7 81.8 NT NT 
Yam2a-1 81.8 6 NT NT 
Yam2c-16 NT NT NT NT 
Vic2c-8 202.5 228 NT NT 
Yam1b-6 26.6 12.6 NT NT 
Yam2b-2 - 113.5 NT NT 
NTNot Tested; IC50 is the sdAb concentration in nM that gives 50% inhibition; and (-) indicates no 
neutralisation activity. 
Both, Vic2a-6 and Vic2a-20 showed a B-Vic lineage-specific neutralisation activity with Vic2a-6 
also showing a low level of neutralisation activity on the earliest post-split B/Yamagata/16/88 strain. 
This was consistent with Vic2a-6 recognising an antigen standard corresponding to the same strain 
(Table 2). 
3.4. Identification of the B Victoria Lineage-Specific Epitope 
For a more precise epitope mapping, we used the yeast surface display which we had previously 
used to epitope map the sdAb binding to HA from A(H1N1)pdm09 [16]. The B/Brisbane/60/2008 HA0 
precursor gene (B-Victoria lineage) (corresponding to the residues D1-I534 of the mature protein) was 
sub-cloned into a yeast display vector, where it was fused to a SV5 epitope tag, enabling the detection 
of a full-length expression and display of the folded HA0 on the yeast surface (Figure 3). Yeast cells 
were simultaneously labelled with an anti-SV5 antibody to determine the HA0 display levels and an 
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anti c-Myc antibody to show binding of the individual sdAbs. The head binding sdAbs Vic2b-3, 
Yam2a-10, Vic2a-20, and the Vic2a-6 bound yeast displayed the B-Victoria lineage HA0, whilst 
YamNGS#1 did not show any binding, which was consistent with its B-Yamagata lineage specificity 
(Table 3) (Figure 4). The stem binding sdAbs did not show any binding which suggested that their 
epitope was not accessible on the yeast cell surface. 
 
Figure 3. Cell sorting and isolation of candidate mutations interfering with the Vic2a-6 sdAb 
binding. Flow cytometry plots for two rounds of negative sorting for loss of binding to Vic2a-6, by 
gating cells in the lower right quadrant of the FACS dot plot, as indicated. Plasmids from the sorted 
yeast clones were sequenced and mutations in the HA which interfered with sdAb binding to HA, 
were identified. Residue numbering was according to B/HongKong/8/73 [29]. 
A library of the B-Victoria lineage HA0 mutants was generated using a low rate error-prone PCR 
to give, approximately, 1 mutation per HA gene [16]. The library was then selected for two rounds, 
for the loss of binding to the B-Victoria lineage-specific sdAb Vic2a-6 (Figure 3). Random clones from 
the sorted population of yeast cells were sequenced to identify HA mutations that were enriched, 
relative to the unselected library, and so were predicted to be residues directly involved in the 
binding epitope. Clones with mutations introducing/replacing cysteine or proline residues were 
discarded, as they were predicted to have indirect effects on the sdAb binding. Several mutations 
were identified relative to the unselected library, which were all mapped within the 120 loop of the 
head domain between residues 116137 (Figure 3), which has previously been identified as an 
antigenic site on the IBV-HA [29,30]. The panel of mutant HAs was tested on the other head binding 
sdAbs, and mutation G133D was shown to interfere with the binding of all head-specific sdAbs, 
equally. Amino acid 133 sits within a highly structured region PGGP, which is consistent with 
having a more destabilising pleiotropic effect. The V124D mutation also interfered with all head 
binding sdAbs, equally, and was also classified as having a pleiotropic effect. Both of these mutations 
could not be associated with lineage-specific binding, so were not investigated further. The I125T 
mutation was also ruled out as a direct contact residue for the Vic2a-6, as it also abolished binding to 
all head binding sdAbs, equally. It is interesting to note that this threonine mutation was also present 
as a naturally occurring variant in the early pre-lineage split strain B/HongKong/08/73, to which 
two of our head binding sdAbs (Vic2a-6 and Vic2a-20) did not bind (Table 2). The remaining residues 
122 and 129, on the other hand, were predicted to correlate with the B-Victoria lineage binding and 
the enrichment of two separate mutations at position 122 (H122L and H122Y), suggested the 
importance of histidine 122 for the binding of Vic2a-6. 
Sequence alignment of the epitope region 116137 of the B-Victoria and the B-Yamagata strains 
tested in ELISA (Table 2), showed that histidine 122 and asparagine 129, spanned regions of 
divergence between the two lineages (Figure 5). We, therefore, re-created three single residue 
mutants in a wild-type HA0 background, H122L, N129D, and a naturally occurring substitution, 
H122Q, where the B-Vic preferred residue (histidine) was substituted with the B-Yam preferred 
residue (glutamine) (Figure 5). Flow cytometry experiments of the sdAb binding to the mutant HA0s 
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(Figure 4), showed that the H122L mutation completely abolished the binding of both Vic2a-6 and 
Vic2a-20, whereas, the H122Q mutation reduced the binding of both sdAbs to between 14% and 24% 
of binding to the wt HA0, confirming the importance of this residue in the epitope footprint of both 
sdAbs (Figure 4). The N129D mutation only interfered with the Vic2a-6 binding, with no effect on the 
Vic2a-20, suggesting that, although these two sdAbs recognized the overlapping epitopes, they were 
not identical. This was consistent with their having unique VHH CDR3 sequences which defined 
their respective paratopes and interactions with HA (Table 2). None of the above three mutations had 




Figure 4. Binding of the sdAbs to the B-Victoria single residue mutant HA0s. Candidate single 
residue mutations predicted to correlate with lineage-specific binding and a naturally occurring 
substitution H122Q, which differentiated between the B-Victoria and B-Yamagata strains, were 
generated and binding was tested using yeast display and flow cytometry. (A) Detection of the HA0 
display level, using detection of the SV5 epitope tag attached to the HA0, showing that the mutations 
had no effect on the HA0 display level relative to the wild-type (wt) HA0 (indicated by vertical arrow). 
(B) Flow cytometry histograms showing binding of the Vic2a-6, Vic2a-20, Vic2b-3 and the YamNGS#1 
to the wild-type HA (B/Brisbane/60/2008 precursor HA0) and selected mutants (the positive 
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population is the right peak, whereas, the left peak shows the unbound and unstained populations). 
Mutations that completely eliminated sdAb binding are shown in red, those that partially affected 
binding are shown in orange and those that had no effect are shown in green. We determined the 
extent of sdAb binding by dividing the geometric mean fluorescence intensity (MFI) of each sdAb 
mutant pair by the value of the MFI of the wild-type B-Vic HA sdAb interaction and the resulting 
ratio, normalised to a percentage value of the wild-type interaction. Relative binding of the sdAbs 
was categorised as no binding (in red)< 5%; intermediate binding (in orange)between 2040%; 
and strong binding (in green)> 40%; shown in the upper right-hand quadrant of the flow 
cytometry histograms. Graphs shown are a representative of at least two independent experiments. 
 
Figure 5. Sequence logo of antigen standards spanning predicted the epitope for lineage-specific, 
head-binding, single domain antibodies. Candidate residues, predicted to have a role in the binding 
epitope footprint of the Vic2a-6 are numbered, according to the B/HongKong/8/73, [29] within 116
137. Alignment of the B-Victoria (top) pre-lineage split strain (middle) and the B-Yamagata strains 
(bottom) are shown for the strains used to determine the sdAb-specificity profile (Table 2). Protein 
sequences used were translated from the DNA sequences: B/Brisbane/60/2008 (gb:ACN29380.1), 
B/Malaysia/2506/2004 (gb:ACR15732.1), B/Shangdong/9/97 (gb:AAM12546.1), B/Victoria/2/87 
(gb:M58428.1) of the B-Victoria lineage; B/Yamagata/16/88 (gb:ABL77255.1), B/Yamanashi/166/98 
(gb: CY019531.1), B/Harbin/7/94 (gb:AF060003.1), B/Jiangsu/10/2003 (gb:ACF54202.1), 
B/Florida/4/2006 (gb:ACF54246.1, B/Massachusetts/02/2012 (gb:KC892118.1), B/Phuket/3037/2013 
(GISAID, EPI529345), B/Utah/9/2014 (gb|AMB72003.1) of the B-Yamagata lineage; and the pre-
lineage split strain B/HongKong/8/73 (gb: AAA43717.1). 
4. Discussion 
Monoclonal antibodies are generally seen as requiring a paired light and heavy-chain to 
recognise a target antigen. However, there are now several examples of stem binding human 
monoclonal antibodies to both IAV and IBV, which only use their heavy-chain for binding, with no 
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contacts being made by the light chain [7,8,10]. Guided by this observation, we have previously used 
alpacas as a route to high-affinity, cross-neutralising, single domain antibodies (NanobodiesTM), 
naturally devoid of a paired LC, which bind to equivalent epitopes in the HA stem of the IAV [14,16]. 
This unique antibody format has several advantages over the conventional MAbs and, in particular, 
their small oblate structure and extended CDR3 loop makes them naturally equipped to access 
grooves and clefts, such as those on viral surfaces [21,31]. In addition, the potential for a smaller 
epitope footprint of the sdAbs, compared with conventional antibodies, which have evolved to bind 
to larger, flatter surfaces, might translate into a higher genetic barrier for an escaping virus and 
retention of binding for a longer period, in evolutionary time. 
Within this study we have identified the sdAbs, specific to the IBV-HA, which have broad cross-
reactivity and lineage-specific recognition. Single domain antibodies Vic1b-10, Yam1b-9, and the 
Yam2a-1 were shown to have a broad cross-reactivity, covering strains spanning over 20 years. This 
clearly shows that these sdAbs bind to the epitopes resistant to antigenic change and could be 
expected to maintain recognition of the influenza B HA, over a significant period of time (Table 2). In 
addition, these sdAbs were capable of neutralizing the influenza lentiviral pseudotypes, 
corresponding to the two prototype viruses representing the two divergent lineages, B/Victoria/2/87 
and B/Yamagata/16/88, suggesting that they might have a potential in immunotherapeutics. Single 
domain antibodies, because of their simple molecular structure, can be easily re-formatted for half-
life extension [32,33]. This could give immediate, short-term immunity, independent of influenza 
vaccination or the need for a functioning immune system. Longer term passive immunity, using 
cross-neutralising antibodies, can be achieved using a viral vector-mediated gene delivery [34,35]. In 
addition, the high stability and ability to withstand nebulisation are distinct advantages of the sdAbs, 
over human antibody formats, and mean intranasal delivery is possible, allowing deep penetration 
into the respiratory tract [36]. The potential applications of the cross-reactive sdAbs against IBV, 
extend beyond immune prophylaxis [10], and include a diagnosis of circulating IBV strains, or 
vaccine potency assays [19,37], for quantitating the HA content of vaccines. 
Given the current requirements of the quadrivalent vaccines we sought to prove that we could 
isolate lineage-specific sdAbs, in a short timeframe, which would be able to maintain reactivity for a 
significant length of time, ideally over several seasonal vaccine changes. The identification of sdAbs, 
which bind to lineage-specific epitopes, is more challenging, given the high sequence and antigenic 
similarity between the lineages. However, using phage display and next-generation sequencing, we 
were able to identify, both, a B-Victoria (Vic2a-6) and a B-Yamagata (YamNGS#1) lineage-specific 
sdAb. Initial attempts using conventional screening to identify B-Yam lineage-specific sdAbs were 
unsuccessful. We reasoned that this was likely due to the low sampling of the selected clones and the 
dominance of the cross-reactive sdAbs during selection. Using NGS, we were able to overcome these 
difficulties and identify a B-Yam lineage-specific sdAb, demonstrating that NGS-assisted screening 
is a useful addition to the phage display process, particularly, in identifying rare sdAb specificities. 
The B-Victoria lineage-specific sdAb Vic2a-6 was shown to neutralise B/Brisbane/60/2008 (B-Victoria) 
but not the B/Florida/04/2006 (B-Yamagata), suggesting that it binds to a lineage-specific epitope in 
the head domain (Table 3). Another sdAb, Vic2a-20, showed preferential binding to the immobilised 
B-Victoria strains, using surface plasmon resonance (Table 3), with a greater than 100-fold higher 
affinity for the B-Victoria than the B-Yamagata HA, which was consistent with the B-Victoria lineage-
specific neutralisation observed (Table 4). This suggests that the Vic2a-20 has a preferred B-Victoria 
lineage-specificity rather than the absolute-specificity shown by the Vic2a-6. The sdAb YamNGS#1 
showed an absolute specificity for the B-Yamagata strains, with no binding to any of the B-Victoria 
strains tested (Table 2). The immunogen used to generate the YamNGS#1 was the 2006 B-Yamagata 
vaccine strain (B/Florida/04/2006) and lineage-specific binding was maintained for a period of 6 years, 
up to the 2012 strain (B/Massachusetts/02/2012). 
In order to understand the structural basis of lineage-specific binding of the sdAb Vic2a-6, we 
used yeast display and mutational scanning [16,38]. Yeast display has emerged as a powerful tool for 
epitope mapping, as its eukaryotic translation machinery acts as a quality control for functional, 
folded, protein variants [39]. In addition, simultaneous selection for, both, display and sdAb binding, 
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using flow cytometric cell sorting means, each protein variant can be selected on the basis of multiple 
parameters. Selection of a HA0 mutant library on Vic2a-6 identified several candidate mutations, 
predicted to specifically interfere with binding. All these mutations lie within the 120 loop spanning 
residues 116137, which is a region of high antigenic diversity [29,30]. The I125T mutation was 
selected from our B-Victoria HA0 mutant library, which is also a naturally occurring substitution 
(Figure 3). Analysis of naturally occurring IBV-HA sequences identified threonine as being present 
in the very early pre-lineage split strain (B/Hongkong/8/73) (Figure 5), which mutated to an isoleucine 
in later IBV strains. The ability to relate the I125T mutation to the absence of binding of Vic2a-6 and 
Vic2a-20, highlighted the potential of yeast display and mutational scanning to correlate sdAb 
binding and strain-specificity profiles to the natural sequence divergence of IBV-HA. Mutational 
scanning predicted that residues 122 and 129 were key residues in the epitope footprint of Vic2a-6. 
The H122L mutation was shown to completely abolish binding of the Vic2a-6 and Vic2a-20, whereas 
N129D completely abolished binding of the sdAb Vic2a-6, with no effect on the binding of Vic2a-20. 
This demonstrated that although these sdAbs epitopes were overlapping, they were also distinct, 
which was consistent with the Vic2a-20 only having a preferred B-Vic lineage-specific binding 
(Table 2). The naturally occurring H122Q mutation associated with the sequence divergence of IBV 
(Figure 5) gave a significant reduction in binding to between 14% and 24% of the wild-type HA 
interaction but did not completely abolish binding. This suggests that this conservative polar 
substitution was associated with B-Victoria lineage-specific binding, but the N129 residue was a more 
significant determinant of the lineage-specific binding of the Vic2a-6. The natural sequence diversity 
at residue 122, in the B-Victoria strains (97% His: 1% Gln), compared to the B-Yamagata strains (94% 
Gln: 5% His) indicated that the preferences for either amino acid, although significant, was not 
complete [30]. The close correlation of binding specificity in ELISA with the identity of residue 122, 
was highlighted by the binding of the Vic2a-6 to B/Yamagata/16/88 (Table 2) and the neutralisation 
of a pseudotype corresponding to this same strain (Table 4). Although this was the earliest B-
Yamagata strain, following the divergence of the two lineages, it maintained a histidine at position 
122, and retained binding to Vic2a-6, which was only lost in the later B-Yamagata strains with the 
substitution of a glutamine. Correlating the mutations which interfere with binding of the Vic2a-6 
and Vic2a-20, with the structure of HA, showed that the epitope footprint was adjacent to the receptor 
binding site and within the 120 loop (Figure 6). The 120 loop was one of the four main regions on the 
influenza B HA1 head domain, identified as being dominant in the antigenic evolution of the most 
recent strains [29,30,40]. The identification of lineage-specific sdAbs, which are able to retain binding 
to an epitope, over such a long period of time (20 years in the case of Vic2a-6 and 18 years in the case 
of YamNGS#1), despite binding to the hyper-variable head domain, was somewhat surprising. It is 
interesting to speculate that this was due to the well-documented ability of sdAbs to bind to small 
grooves and pockets on protein surfaces, which might represent a higher genetic barrier for escape 
than conventional antibodies which bind to larger flatter surfaces [16]. 
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Figure 6. Correlation of the sdAb epitopes with the Hemagglutinin structure. The structure of the 
HA0 monomer (B/Brisbane/60/2008 PDB structure 4FQM) is shown with the HA1 domain in blue, the 
stem region in grey, the 120 loop in yellow and the receptor binding site (RBS) in green. The residue 
of H122 and N129 associated with the B-Victoria lineage-specific binding of the sdAb Vic2a-6 or 
preferred binding of the Vic2a-20 are shown in red. The binding specificity of the sdAb panel are 
shown in relation to the HA head and stem region. 
We have shown that it is possible to isolate high-affinity, cross-reactive and lineage-specific 
sdAbs from alpacas immunised with a single seasonal vaccine strain, which can maintain binding 
and resistance to natural antigenic changes, over a significant period of time. We have also 
highlighted that next-generation sequencing analysis of phage displayed libraries can be useful in 
identifying sdAbs that may have been missed using more limited conventional ELISA-based 
screening. In addition, using yeast display and mutational scanning we have been able to correlate 
the lineage-specific binding with the structure of HA and have related natural antigenic diversity 
within this epitope with the sdAb (NanobodyTM) reagent binding. This suggests that yeast display 
epitope mapping could be adapted to give a comprehensive analysis of the epitope of lineage-specific 
sdAbs, which could be used for quadrivalent vaccine potency testing, and in addition, it could predict 
when a sdAb might lose its binding and needs updating [37]. 
Supplementary Materials: The following are available online at www.mdpi.com/2073-4468/8/1/14/s1, Figure S1: 
Isolation of the B-Yamagata lineage-specific nanobodies, using NGS. High copy number CDR3s using antibody 
mining toolbox (A) were normalised for each sequencing run and presented as % Relative Frequency (B,C). Fold 
increase in CDR3 frequencies were then calculated from a CDR3 frequency, in the unselected phage library and 
the same CDR3s frequency after selection of the HA1 domain, or of the full-length HA0 (D,E), Figure S2: 
Grouping as head- or stem-specific binding using surface plasmon resonance (SPR). The kinetic binding 
constants (kon and koff) of the panel of nanobodies were determined using SPR and single-cycle kinetics. Data 
are presented as rate plots with iso-affinity diagonals (RAPID) where the diagonals (dotted lines) are connecting 
the points of equal dissociation constant (KD). Affinity on (A) the B-Yamagata head domain (HA1) of the 
B/Florida/04/2006, (B) the full-length HA0 of the B/Florida/04/2006, (C) the B-Victoria head domain (HA1) of the 
B/Brisbane/60/2008, and (D) the full length HA0 of the B/Brisbane/60/2008, is shown. Fitting was with single-
Antibodies 2019, 8, 14 9 of 20 
 
cycle kinetics and a 1:1 Langmuir fitting model, using the BIAevaluationTM software ((GE Healthcare, 
Marlborough, MA, USA). Equilibrium dissociation constants are given in Table 3.  
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